MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/hepr.14216

Медицинская библиотека · Hepatology research : the official journal of the Japan Society of Hepatology · 2025

Predicting the risk of developing diabetes in steatotic liver disease using controlled attenuation parameter in a health checkup population.

Nakatsuka Takuma, Yamaji Yutaka, Tateishi Ryosuke, Ogasawara Takako, Mihara Rena, Kawashima Yoshiaki, Ono Tetsuharu, Yamada Tomoharu, Minami Tatsuya, Sato Masaya, Hayashi Takeshi, Matsushita Yuki, Funato Kazuyoshi, Sato Tatsuya, Saito Tomotaka, Kudo Yotaro, Kogure Hirofumi, Nakagawa Hayato, Asaoka Yoshinari, Tanaka Yasuo, Nakai Yousuke, Ijichi Hideaki, Fujishiro Mitsuhiro

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Excessive hepatic steatosis is linked to systemic metabolic disorders. We investigated the association between hepatic steatosis quantified by controlled attenuation parameter (CAP) and the development of type 2 diabetes mellitus (T2DM) in a health checkup population.

METHODS

The present retrospective cohort study included 1636 participants without T2DM who underwent CAP measurement and were followed up at annual health checkups. Cox proportional hazards regression was used to identify risk factors for T2DM development.

RESULTS

During a mean follow-up of 3.2 years, 181 participants developed T2DM. The cumulative incidence rates of T2DM were significantly higher in participants with severe steatosis (CAP ≥ 280 dB/m) compared with those without (13.9% vs. 4.8% at 3 years, p < 0.001). Multivariate analysis identified CAP as an independent predictor of new-onset T2DM (adjusted hazard ratio [aHR], 1.04 per 10 dB/m increase; 95% confidence interval [CI], 1.01-1.08, p = 0.01), along with fasting plasma glucose (aHR, 2.13 per 10 mg/dL; 95% CI, 1.77-2.55, p < 0.001), HbA1c (aHR, 1.25 per 0.1% increase; 95% CI, 1.19-1.32, p < 0.001), and platelet count (aHR, 0.95 per 104/μL increase; 95% CI, 0.92-0.98, p = 0.001). A dose-response relationship was observed between CAP level and T2DM risk. In addition, suspected compensated advanced chronic liver disease (liver stiffness ≥10 kPa) and at-risk steatohepatitis (FibroScan-AST score ≥0.67) were associated with a higher incidence of T2DM (p < 0.001 for both).

CONCLUSION

CAP quantification of hepatic steatosis effectively stratifies the risk of developing T2DM, facilitating timely intervention and prevention strategies.

Для цитирования: Nakatsuka Takuma, Yamaji Yutaka, Tateishi Ryosuke, Ogasawara Takako, Mihara Rena, Kawashima Yoshiaki, Ono Tetsuharu, Yamada Tomoharu, Minami Tatsuya, Sato Masaya, Hayashi Takeshi, Matsushita Yuki, Funato Kazuyoshi, Sato Tatsuya, Saito Tomotaka, Kudo Yotaro, Kogure Hirofumi, Nakagawa Hayato, Asaoka Yoshinari, Tanaka Yasuo, Nakai Yousuke, Ijichi Hideaki, Fujishiro Mitsuhiro. Predicting the risk of developing diabetes in steatotic liver disease using controlled attenuation parameter in a health checkup population.. Hepatology research : the official journal of the Japan Society of Hepatology. 2025. DOI: 10.1111/hepr.14216.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.